Search Results

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

Czech Republic Leads EU Project to Assess Application of Commercial-Grade Items in VVER Nuclear Power Plants

The Czech State Office for Nuclear Safety (SÚJB) has launched a two-year EU project focused on assessment methodologies for the application of high-quality commercial-grade items in nuclear power plants equipped with VVER reactors. The project aims to establish a unified, expert-judgment-based evaluation process that provides methodological support for nuclear facilities when introducing relevant items, while ensuring that nuclear safety requirements are not compromised. As the nuclear power supply chain landscape evolves, certain plant-specific components may face the need to be replaced by commercial-grade products. In response, regulatory authorities need to establish clear rules to review the suitability, quality assurance, and safety implications of substitute items. The project will focus on evaluating...

2026-08-04

Antineutrinos Detected for the First Time in Spent Fuel Elements

Even after a nuclear reactor has been shut down, the radioactive fuel continues to emit a faint stream of antineutrinos. The Double Chooz collaboration, led by scientists from the Max Planck Institute for Nuclear Physics (MPIK), has succeeded for the first time in measuring this elusive signal, opening up new prospects for reactor monitoring, nuclear safety, and control procedures. The Double Chooz detector. Image credit: Double Chooz collaboration. The research team conducted these measurements at the Chooz nuclear power plant in northern France. The Double Chooz detector is located approximately 400 meters underground, in close proximity to two reactor cores. Inside, the detector contains more than 30 cubic meters of liquid scintillator material...

2026-08-04

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

Study Shows Sustained Deuterium Fusion in Palladium and Titanium Metal Foils at Ultra-Low Energies

U.S. researchers have observed a low-energy deuterium fusion phenomenon in thin palladium and titanium metal foils: when the incident deuteron energy drops to levels where fusion reactions are generally expected to weaken significantly or even nearly cease, the reactions continue to occur. Experiments show that as incident energy decreases, the fusion rate does not continue to decline exponentially but instead enters a plateau region below approximately 2 keV. At the lowest detectable energy, the measured low-energy fusion rate exceeds predictions from isolated-nucleus models by more than 10^18 times. Image courtesy of Marina Light/University of California, Davis. The related research was conducted by teams at the University of California, Davis and Lawrence Berkeley National Laboratory...

2026-08-04

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

Swiss PSI Ultracold Neutron Experiment Finds No Signs of "Mirror World" Oscillation

The Paul Scherrer Institute (PSI) in Switzerland announced on July 28 that its researchers detected approximately 25 billion neutrons in an ultracold neutron experiment and found no signs of neutrons spontaneously transforming into mirror neutrons. The results constrain, with high certainty, the theoretical possibility of neutrons disappearing into the so-called mirror world. The mirror world hypothesis posits that every elementary particle in the real world may have a corresponding mirror particle, such as mirror electrons, mirror protons, and mirror neutrons. Such particles interact extremely weakly with ordinary matter, potentially connecting primarily through gravity or rare oscillations of neutral particles, and have therefore also been considered as dark matter candidates...

2026-08-03

German Science and Humanities Council Supports German Participation in the LEGEND-1000 Neutrinoless Double Beta Decay Experiment

On July 27, 2026, the German Science and Humanities Council expressed its support for German participation in the LEGEND-1000 experiment. The project had previously passed scientific evaluation and was deemed significant for a broad research community in the fields of particle physics and nuclear physics. LEGEND-1000 is the next phase of the large-scale enriched germanium neutrinoless double β decay experiment, planned to be constructed by an international collaborative team at the underground laboratory of the Gran Sasso National Laboratory in Italy. German participating institutions include the Max Planck Institute for Nuclear Physics in Heidelberg and the Technical University of Munich, with project leaders being Professor Susanne Mertens and Professor Stefan Schönert, respectively. According to the project...

2026-08-03

Bolivia Advances Legislative Process for Peaceful Nuclear Technology Applications

EL ALTO, Bolivia, July 29 - The Bolivian Nuclear Energy Agency (ABEN) recently held working exchanges with relevant committees of the Plurinational Legislative Assembly to discuss the reactivation of related legislative agendas, focusing on the continued advancement of Bolivia's nuclear energy program and peaceful nuclear technology application projects. René Soria Sausedo, Executive Director of ABEN, stated that as the primary operating entity of Bolivia's nuclear program, ABEN bears the responsibility of driving the implementation of peaceful nuclear technology application projects. These efforts require modern legal instruments to define institutional mandates, technical standards, and the fundamental legal framework for project development. The parliamentary delegation, led by the President of the International Policy and Migration Protection Committee, visited ABEN facilities...

2026-08-03

DUNE Prototype Detector Undergoes 300 kV Pressure Test at CERN

The Deep Underground Neutrino Experiment (DUNE), an international collaborative project led by the Fermi National Accelerator Laboratory under the U.S. Department of Energy, is conducting pressure tests on the prototype detector ProtoDUNE at CERN's Neutrino Platform to verify the long-term stability of the relevant detection technology under extreme operating conditions. DUNE is designed as a large-scale neutrino research experiment aimed at studying the properties of neutrinos and their role in the evolution of the universe. The experiment will install large liquid argon time projection chamber detectors approximately one mile underground at the Sanford Underground Research Facility in South Dakota, USA. Once the detectors are filled with liquid argon and sealed, internal components will be difficult to access for extended periods...

2026-08-03

Russia's Vector Research Center Proposes Quantum Dots for Boron Delivery in Neutron Capture Therapy

Russia's Vector Research Center has proposed using quantum dots as targeted boron delivery systems in boron neutron capture therapy (BNCT) to explore more precise approaches to tumor treatment. Yuri Tumanov, the center's chief researcher, presented this research progress at a conference on engineering biology and biopharmaceuticals. Boron neutron capture therapy is a cancer treatment method that combines boron-containing drugs with neutron irradiation. The basic concept involves first allowing boron-containing drugs to accumulate in tumor cells, then subjecting the patient to neutron irradiation, which triggers a nuclear reaction that releases energy concentrated within boron-containing cancer cells, thereby destroying tumor cells. How to construct boron delivery systems that are low-toxicity, highly efficient, and capable of participating in targeted tumor destruction remains one of the key challenges in this field...

2026-08-01

Thor Medical Launches Commercial Production of Lead-212 at AlphaOne Facility

Thor Medical ASA announced on July 31 that commercial production has commenced at its industrial-scale AlphaOne production facility located in the Herøya industrial park. The facility will produce lead-212 (Pb-212) and its precursors thorium-228 (Th-228) and radium-224 (Ra-224) to support demand related to radiopharmaceuticals and targeted cancer radiotherapy. According to the company, Thor Medical has signed supply agreements with multiple types of customers across the radiopharmaceutical value chain, including startup biotechnology companies, contract development and manufacturing organizations (CDMOs), and global pharmaceutical companies. The company expects the AlphaOne facility to deliver its first products to customers in August 2026. AlphaOn...

2026-08-01

Mangoceuticals to Merge with Nuclea to Advance Morpheus Microreactor to Market

Mangoceuticals announced on July 30 that it has signed a definitive business combination agreement with advanced nuclear technology company Nuclea Energy Inc., aiming to bring the latter's Morpheus microreactor to the public capital markets. Nuclea was founded in August 2023 and is headquartered in Mississauga, Ontario, Canada, focusing on the development of lead-cooled, factory-fabricated micro-modular reactors. Under the agreement, a newly formed subsidiary of Mangoceuticals will merge with Nuclea, and the combined company will operate as an indirect wholly owned subsidiary of Mangoceuticals. Upon completion of the transaction, holders of Nuclea common shares will receive...

2026-07-31

Europe Completes Manufacturing of JT-60SA Pellet Centrifuge Accelerator

The European Fusion Energy Organization (F4E) recently announced progress on key components of a new pellet injection system for the upgrade of the JT-60SA device. The centrifuge accelerator, manufactured by Sener, has been completed and delivered to the Max Planck Institute for Plasma Physics (IPP). It will subsequently be integrated with other components of the pellet injection system and undergo testing. The operation of fusion devices relies on the continuous supply of hydrogen isotope fuel. In devices such as JT-60SA and the International Thermonuclear Experimental Reactor (ITER), the pellet injection system is used to fuel the plasma and assist in controlling plasma instabilities. The system typically consists of three parts: preparation...

2026-07-29